Shares of EyePoint Pharmaceuticals (NASDAQ: EYPT) plummeted 9.04% in Wednesday's trading session following the release of the company's disappointing third-quarter 2025 financial results. The clinical-stage biopharmaceutical firm, focused on developing treatments for serious eye diseases, reported wider losses and a significant revenue decline that fell short of analyst expectations.

For the quarter ended September 30, 2025, EyePoint reported a net loss of $59.7 million, or $0.85 per share, compared to a loss of $29.4 million, or $0.54 per share, in the same period last year. The loss per share of $0.85 missed the analyst consensus estimate of $0.79. Total revenue for the quarter plummeted to $1.0 million, a stark 90.5% decrease from $10.5 million in the prior-year period, and significantly below the analyst consensus estimate of $3.329 million.

The company attributed the increased losses to higher operating expenses, which rose to $63.0 million from $43.3 million in the previous year. This surge was primarily driven by escalating clinical trial costs related to ongoing Phase 3 trials for DURAVYU, EyePoint's lead product candidate for wet age-related macular degeneration (AMD). Despite the widening losses, EyePoint highlighted its recent $172.5 million oversubscribed equity financing, which is expected to extend its cash runway into the fourth quarter of 2027. This financial cushion is crucial as the company continues to advance its clinical programs, including the anticipated data readout from its LUGANO Phase 3 trial for DURAVYU in mid-2026.